PSORÍASE E ATEROSCLEROSE SUBCLÍNICA: O IMPACTO DA INFLAMAÇÃO SISTÊMICA
LUMEN ET VIRTUS · 10.08.2026 · 17 (63) · e13991
DOI: 10.56238/levv17n63-019 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUMEN ET VIRTUS, online erschienen am 10.08.2026. Verfasst von Anne Katlen Damasceno Uchoa Thome und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Psoriasis is a chronic immune-mediated inflammatory disease associated with cardiometabolic comorbidities and an increased risk of atherosclerotic cardiovascular disease (ASCVD). Persistent systemic inflammation may promote endothelial dysfunction, arterial stiffness, vascular remodeling, and coronary plaque formation before clinically apparent cardiovascular events occur.
Objective
To analyze the relationship between psoriasis, systemic inflammation, and subclinical atherosclerosis, with emphasis on shared pathophysiological mechanisms, diagnostic methods, clinical risk factors, and the potential vascular effects of systemic anti-psoriatic therapy.
Methods
A narrative review was conducted using PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, and LILACS. Clinical studies, observational cohorts, randomized trials, systematic reviews, meta-analyses, and consensus documents assessing structural, functional, inflammatory, or imaging markers of subclinical atherosclerosis in adults with psoriasis were considered. Studies evaluating carotid intima-media thickness, coronary artery calcium, coronary computed tomography angiography, flow-mediated dilation, pulse-wave velocity, and vascular inflammatory imaging were prioritized. Results and Discussion: The available evidence indicates that patients with psoriasis may present increased carotid arterial-wall thickness, coronary calcification, noncalcified coronary plaque, endothelial dysfunction, arterial stiffness, and vascular inflammation. These abnormalities are more frequently observed in individuals with moderate-to-severe disease, longer disease duration, psoriatic arthritis, obesity, diabetes mellitus, dyslipidemia, hypertension, or smoking. Observational studies suggest that biological therapy may improve selected vascular and coronary imaging markers, although randomized evidence remains inconsistent and no specific therapy has definitively demonstrated a reduction in major cardiovascular events through suppression of psoriatic inflammation alone. The heterogeneity of study populations, imaging methods, treatments, and confounding factors limits the establishment of a universal screening strategy.
Conclusion
Psoriasis is associated with a greater probability of subclinical vascular injury, particularly when systemic inflammation coexists with conventional cardiometabolic risk factors. Cardiovascular prevention should combine effective control of psoriatic disease with systematic assessment and treatment of modifiable risk factors. Advanced vascular imaging should be reserved for selected patients in whom conventional risk assessment may underestimate long-term cardiovascular burden.
Zitieren
APA
Thome, A. K. D. U., Lima, L. C. D. S., Jesus, I. R. Z. D., Henckel, M. C. R., Areias, J. V. D. S., & Ribeiro, B. A. (2026). PSORÍASE E ATEROSCLEROSE SUBCLÍNICA: O IMPACTO DA INFLAMAÇÃO SISTÊMICA. LUMEN ET VIRTUS, 17(63), e13991. https://doi.org/10.56238/levv17n63-019
Vancouver
Thome AKDU, Lima LCDS, Jesus IRZD, Henckel MCR, Areias JVDS, Ribeiro BA. PSORÍASE E ATEROSCLEROSE SUBCLÍNICA: O IMPACTO DA INFLAMAÇÃO SISTÊMICA. LUMEN ET VIRTUS. 2026;17(63):e13991. doi:10.56238/levv17n63-019
BibTeX
@article{Thome2026,
author = {Thome, Anne Katlen Damasceno Uchoa and Lima, Luciano Custódio Dos Santos and Jesus, Isabela Rizzieri Zaque de and Henckel, Maria Cecília Rodrigues and Areias, João Victor Da Silva and Ribeiro, Beatriz Almeida},
title = {PSORÍASE E ATEROSCLEROSE SUBCLÍNICA: O IMPACTO DA INFLAMAÇÃO SISTÊMICA},
journal = {LUMEN ET VIRTUS},
year = {2026},
volume = {17},
number = {63},
pages = {e13991},
doi = {10.56238/levv17n63-019}
}
EUVIMED